People · Operator

Ryan Lund

Named in public records as an officer, director or promoter · active 2016–2020 · Pharmaceuticals, AI / ML

2
Companies
2
Filings
$48.8M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Clene Nanomedicine, Inc.PharmaceuticalsSeries C$48.7M$1.4B2020
Cerebri AI Inc.AI / MLPre-Seed$125K$6.9M2016
Operator network

Ryan Lund at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

John Stevens · 6 companies · 1 sharedJohn StevensShalom Jacobovitz · 3 companies · 1 sharedShalom JacobovitzAlison Mosca · 2 companies · 1 sharedAlison MoscaReed Wilcox · 2 companies · 1 sharedReed WilcoxChad Young · 1 companies · 1 sharedChad YoungDavid Lisonbee · 1 companies · 1 sharedDavid LisonbeeRobert Gay · 1 companies · 1 sharedRobert GayRob Etherington · 1 companies · 1 sharedRob EtheringtonMichael Roberts · 10 companies · 1 sharedMichael RobertsJean Belanger · 3 companies · 1 sharedJean BelangerMark Castleman · 3 companies · 1 sharedMark CastlemanARUN PRAKASH · 2 companies · 1 sharedARUN PRAKASHGABBY SILBERMAN · 1 companies · 1 sharedGABBY SILBERMANKAREN BENNET · 1 companies · 1 sharedKAREN BENNETSTEVE ELMORE · 1 companies · 1 sharedSTEVE ELMOREClene Nanomedicine, Inc. · $48.7M raisedClene Nanomedicine, I…Cerebri AI Inc. · $0.1M raisedCerebri AI Inc.Ryan LundRL
Ryan Lund Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Ryan Lund on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Michael Roberts110
John Stevens16
Shalom Jacobovitz13
Jean Belanger13
Mark Castleman13
Reed Wilcox12
ARUN PRAKASH12
Alison Mosca12
GABBY SILBERMAN11
Chad Young11
David Lisonbee11
Robert Gay11
Rob Etherington11
KAREN BENNET11
STEVE ELMORE11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.